Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease

Ming Jang Chiu*, Shieh Yueh Yang, Herng Er Horng, Che Chuan Yang, Ta Fu Chen, Jen Je Chieh, Hsin Hsien Chen, Ting Chi Chen, Chia Shin Ho, Shuo Fen Chang, Hao Chun Liu, Chin Yih Hong, Hong Chang Yang


研究成果: 雜誌貢獻期刊論文同行評審

115 引文 斯高帕斯(Scopus)


A highly sensitive immunoassay, the immunomagnetic reduction, is used to measure several biomarkers for plasma that is related to Alzheimer's disease (AD). These biomarkers include Aβ-40, Aβ-42, and tau proteins. The samples are composed of four groups: healthy controls (n = 66), mild cognitive impairment (MCI, n = 22), very mild dementia (n = 23), and mild-to-serve dementia, all due to AD (n = 22). It is found that the concentrations of both Aβ-42 and tau protein for the healthy controls are significantly lower than those of all of the other groups. The sensitivity and the specificity of plasma Aβ-42 and tau protein in differentiating MCI from AD are all around 0.9 (0.88-0.97). However, neither plasma Aβ-42 nor tau-protein concentration is an adequate parameter to distinguish MCI from AD. A parameter is proposed, which is the product of plasma Aβ-42 and tau-protein levels, to differentiate MCI from AD. The sensitivity and specificity are found to be 0.80 and 0.82, respectively. It is concluded that the use of combined plasma biomarkers not only allows the differentiation of the healthy controls and patients with AD in both the prodromal phase and the dementia phase, but it also allows AD in the prodromal phase to be distinguished from that in the dementia phase.

頁(從 - 到)1530-1536
期刊ACS Chemical Neuroscience
出版狀態已發佈 - 2013 12月 18

ASJC Scopus subject areas

  • 生物化學
  • 生理學
  • 認知神經科學
  • 細胞生物學


深入研究「Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease」主題。共同形成了獨特的指紋。